Key facts
- MingMed Biotech’s last known valuation is $615.4M (Jul 2022).
- It has raised $139.8M; the latest was Later Stage VC ($3.5M) in Apr 2025.
- Notable investors include CAS Star, Shenzhen Yifeng Investment Management Enterprise, Oceanpine Capital, Hengqin Financial Investment, Taiping Life Insurance Company — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for MingMed Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for MingMed Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MingMed Biotech
Developer of pharmaceutical drugs intended for global pharmaceutical markets and healthcare providers. The company develops ophthalmic drugs, small-molecule immune drugs, and cell therapies based on gene editing, thereby providing innovative products to ophthalmology, medical beauty, and pet medicine.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2019
- Employees
- 230
- Website
- ming-med.com/
- Ownership
- Privately Held (backing)
MingMed Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MingMed Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MingMed Biotech in its N-PORT filings yet. We sweep new filings monthly.